CCG
BBH icon

Cypress Capital Group’s VanEck Biotech ETF BBH Stock Holding History

Cypress Capital Group’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,440
Closed -$201K – 207
2019
Q4 		$201K Buy
+1,440
New +$189K 0.04% 234

Other funds holding BBH

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
MJRIC
Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
BRM
Boston Research & Management Manchester, Massachusetts $421M AUM 16.18% 1-Year Est. Return

Cypress Capital Group's BBH Position: Q1 2020 in Review

Cypress Capital Group sold out of VanEck Biotech ETF (BBH) in Q1 2020, closing a stake of 1,440 shares — an estimated $201K sold.

Cypress Capital Group first reported a position in BBH in Q4 2019 and held it in 1 quarter. The position peaked at $201K in Q4 2019. 83 funds tracked by Wall St. Rank hold BBH as of Q1 2020.

  • Cypress Capital Group reported no remaining VanEck Biotech ETF position as of Q1 2020 after selling out during the quarter.
  • Cypress Capital Group sold 1,440 VanEck Biotech ETF shares in Q1 2020, an estimated $201K.
  • Cypress Capital Group first reported a position in VanEck Biotech ETF in Q4 2019 and held it in 1 quarter.
  • Cypress Capital Group's VanEck Biotech ETF position peaked at $201K in Q4 2019.
  • 83 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2020.

Based on Cypress Capital Group's 13F filing for Q1 2020, filed 8 Apr 2020.